Table 2 : Summary of measurements at baseline, 8 and 16 months for 19 participants completing 16-month programme. Clinical measurements are expressed as mean ± sd; biochemical measurements as median [interquartile range].

  Baseline 8months 16 months 0 v 8m p 0 v 16m p 8 v 16m
  Mean+sd    
Weight, kg 96.2±17.9 88.1±16.8 90.5±17.5 <0.001 <0.001 0.01
BMI, kg/m2 33.3±5.3 30.6±5.2 31.2±5.4 <0.001 <0.001 0.009
Waist Circumference 111.9±13.4 99.6±14.5 102.0±14.7 <0.001 <0.001 0.008
% Body Fat, % 39.1±8.8 33.9±8.3 37.2±6.8 <0.001 0.007 0.02
Systolic BP, mm Hg 146.7±20.5 127.8±11.5 139.3±14.8 <0.001 ns ns
Diastolic BP, mm Hg 83.8±11.1 71.6±7.9 72.4±7.5 <0.001 <0.001 ns

  Median [IQ Range]      

HbA1c, mmol/mol 47.5 [12.6] 44.3 [7.6] 45.4 [9.3] <0.01 ns 0.001
HbA1c, % 6.6  [1.3] 6.1 [0.9] 6.3 [0.9]
Fasting Glucose, mmol/L 6.4 [1.0] 6.0 [0.9] 5.8 [0.65] <0.001 ns ns
Fasting Insulin, mIU/L 12.6 [8.7] 7.6 [4.4] 12.0 [6.1] <0.001 ns 0.02
HOMA – IR 3.81 [2.3] 1.76 [1.6] 3.1 [2.1] <0.001 ns 0.04
Cholesterol, mmol/L 4.5 [1.35] 4.1 [1.4] 4.0 [1.4] ns ns ns
Triglycerides, mmol/L 2.0 [1.25] 1.3 [1.1] 1.7 [0.9] ns ns ns
HDL-C, mmol/L 1.06 [0.45] 1.2 [0.4] 1.1 [0.6] <0.001 0.04 ns
GLP-1 Basal, pmol/L 2.15 [1.40] 2.51 [1.55] 2.9 [0.7] ns - -
GLP-1 30’, pmol/L 6.5 [7.4] 6.8 [5.0] - ns - -
Leptin, µg/ml 39.4 [36.5] 15.5 [17.2] 26.8 [31.9] <0.01 ns 0.003
Adiponectin, µg/L 6.85 [2.95] 6.0 [7.0] 8.2 [3.9] ns ns ns

Kerr et al.Journal of Diabetes Research and Clinical Metabolism  2013 2:10DOI : 10.7243/2050-0866-2-10